Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.25
Bid: 20.00
Ask: 20.50
Change: -0.75 (-3.57%)
Spread: 0.50 (2.50%)
Open: 21.50
High: 21.50
Low: 20.25
Prev. Close: 21.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

OptiBiotix obtains BRC accreditation

5 Jan 2022 07:00

RNS Number : 4249X
OptiBiotix Health PLC
05 January 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

OptiBiotix obtains British Retail Consortium accreditation

One of the leading international food safety standards

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing unique science and human study-based compounds that modulate the microbiome to address metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and to support healthy aging has achieved British Retail Consortium ('BRC') accreditation.

 

BRC was the first standard to meet the Global Food Safety Initiative ('GFSI') benchmark, which means it is accepted by many of the world's biggest retailers, such as Tesco and Walmart. The certification ensures customers have confidence in OptiBiotix's products and it allows the Company to do business with those retailers, manufacturers, ingredients companies and food service organisations who specify certification as part of their approval process (most large retailers and their suppliers). It incorporates food safety management systems and internationally accepted best practice to ensure the safety and quality of products and in doing so reduces the risk of recalls.

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased to announce our BRC accreditation which supports our commercial strategy of selling final product solutions to partners in the retail channel containing our science backed pro and prebiotic ingredients. I am particularly proud of our team which achieved this accreditation in a relatively short period of time."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASSUFWLEESEFF
Date   Source Headline
25th Mar 20247:00 amRNSPlacing, Subscription and Director Dealing
18th Mar 202411:36 amRNSHolding(s) in Company
13th Mar 20247:00 amRNSPartnership agreement with Morepen for SlimBiome
8th Mar 20244:09 pmRNSHolding(s) in Company
27th Feb 20247:00 amRNSStrategic and commercial update
9th Feb 20247:00 amRNSChange of auditor
5th Feb 20247:00 amRNSPresentation at ProBiota 2024
30th Jan 20247:00 amRNSSweetBiotix Update
15th Jan 20247:00 amRNSLaunch of LeanBiome in Muscletech
4th Dec 20237:00 amRNSDirectorate Change
28th Nov 20237:00 amRNSDistribution agreement for SlimBiome
24th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 20237:00 amRNSBBSRC Grant for WellBiome®
1st Nov 20237:00 amRNSCommercial update
23rd Oct 20237:00 amRNSLicense agreement with Tata Chemicals
19th Oct 20233:02 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSHalf-year Report
22nd Sep 20237:00 amRNSPlanned launch of OptiBiotix products with Boots
29th Aug 20237:00 amRNSCommercial update
31st Jul 202312:51 pmRNSHolding(s) in Company
26th Jul 202312:34 pmRNSResult of AGM
19th Jul 20237:00 amRNSSweetBiotix® overview
28th Jun 20237:00 amRNSFinal Results
4th May 20237:00 amRNSInvestor update
21st Mar 20237:00 amRNSChange of Broker
15th Mar 20237:00 amRNSSlimbiome study results
21st Feb 20237:00 amRNSDirectorate Change
30th Jan 20234:28 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIssue of Equity – Subscription
10th Nov 202211:30 amRNSInvestor update
1st Nov 20227:00 amRNSLaunch of GoFigure products on Tmall China
24th Oct 20227:00 amRNSApproval of GoFigure products
17th Oct 20227:00 amRNSNew health claims for SlimBiome in Australia
17th Oct 20227:00 amRNSNew health claims for SlimBiome in Australia
28th Sep 20227:00 amRNSHalf-year Report
26th Sep 20227:00 amRNSLaunch of novel prebiotic in Europe and Africa
20th Sep 20227:00 amRNSLaunch of GoFigure range with Apollo Hospitals
14th Sep 20227:00 amRNSNew commercialisation partner in Asia Pacific
24th Aug 20224:41 pmRNSSecond Price Monitoring Extn
24th Aug 20224:35 pmRNSPrice Monitoring Extension
24th Aug 20222:06 pmRNSSecond Price Monitoring Extn
24th Aug 20222:00 pmRNSPrice Monitoring Extension
24th Aug 202211:06 amRNSSecond Price Monitoring Extn
24th Aug 202211:00 amRNSPrice Monitoring Extension
24th Aug 20229:05 amRNSSecond Price Monitoring Extn
24th Aug 20229:00 amRNSPrice Monitoring Extension
24th Aug 20227:00 amRNSTrading update
26th Jul 202212:31 pmRNSResult of AGM
20th Jul 20227:00 amRNSCommercial and scientific update
11th Jul 20227:00 amRNSJoint development agreement signed with Firmenich

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.